WillItSurvive
YC Fall 2025 · United States

Remedy

AI phone agent that answers routine calls for independent community pharmacies.

Little protection left
Assessed 27 July 2026 · Evidence as of 27 July 2026
Not much stands between this business and its pressures.
On the recordSince 27 July 2026 · Checkable from H2 2026 · Every call on the record Checkpoint: Other states deciding whether to follow Utah's Doctronic model allowing AI to autonomously renew prescriptions
The call

Remedy sits in a doorway that generic voice AI platforms and bigger-funded rivals like Asepha and Hippocratic AI can already walk through.

Remedy uses artificial intelligence to answer phone calls for pharmacies, taking in customer requests without a human. The problem is that this type of service is getting cheaper and easier to build; Hippocratic has raised over a billion dollars, Retell and PolyAI already offer the same thing to any pharmacy that wants it, and big chains like CVS or Walgreens could build this themselves. Remedy chose to stay in the simplest, easiest part of the pharmacy workflow (just answering the phone), which means there is almost nothing stopping a pharmacy from switching to a cheaper option or a bigger company. The one thing that could save Remedy is if it can lock in a major pharmacy chain as an exclusive customer, or move into a harder job (like actually processing prescription renewals, which requires government approval and is harder to copy) instead of just taking messages.

Why
01
AI pressure: Retell AI, PolyAI, and Hippocratic AI pharmacy-refill voice templates. Generic AI voice platforms already ship pharmacy-refill templates, so Remedy's core feature is copyable by anyone with a phone API. Could AI do the core job? Yes, likely.
02
Bigger players: Large retail pharmacy chains (CVS/Walgreens scale) and PMS vendors like PioneerRx. Big chains already run in-house AI call systems handling over a million calls a day, leaving Remedy the smaller independents that chains don't bother with. Could a giant copy it? Yes, easily.
03
What protects it. Staying in the low-risk, intake-only lane (no dosage advice, no prescription changes) keeps liability low and lets it onboard independent pharmacies fast without regulatory friction.
What would change this call
Remedy announces a signed seed round or names an enterprise pharmacy customer within two quarters. Would show it can secure capital or distribution against better-funded rivals.
Asepha or Hippocratic AI announces a named large pharmacy chain deployment. Would confirm rivals are capturing the same customer segment Remedy targets.
A state beyond Utah approves autonomous prescription-renewal AI authority. Would show whether the regulated layer Remedy avoids is opening to competitors first.
Key numbers
  • Asepha (rival) raised $4M seed, 5x oversubscribed (2025-07-14)
  • Hippocratic AI raised $141M at $1.64B valuation (2025-01-01)
  • Utah AI renewal pilot covers ~80% of medication renewals (2026-04-29)
Named risks
  • No independently confirmed funding round as of 2026-07, threatening runway and survival. Severity: high
  • Crowded niche with better-funded direct competitors (Asepha, Hippocratic AI) shipping same workflow. Severity: high
  • No demonstrated exclusive PMS integration or regulatory moat versus generic voice platforms. Severity: high
  • Very small team (approx. 3 people per aggregator data) limits execution speed against funded rivals. Severity: medium
  • Deliberately intake-only scope avoids the regulatory clinical layer that could differentiate the product. Severity: medium
Rivals, as read in July 2026
RivalDirectionEvidence
Asephagaining onRaised $4M oversubscribed seed 2025-07-14, claims Fortune 50 customers, doubling staff
Hippocratic AIgaining onClosed $141M Series B at $1.64B valuation, Jan 2025, incumbent-scale capital
Pharmie AIcontestingYC-backed rival building identical 'AI pharmacy technician' with PMS integration
Retell AI / PolyAIgaining onShipped pharmacy-refill voice templates by 2026-06-30, commoditizing core use case
Large retail pharmacy chains (in-house)losing toOne 7,000+ store chain already handles 1M+ calls/day with in-house AI, per 2026-04-07 report
Questions people ask
Is Remedy profitable in 2026?
No revenue or profitability figures have been disclosed. Remedy is a YC Fall 2025 batch startup still in pilot stage, describing its product as an 'Initial Pharmacy Pilot' as of mid-2026, with no confirmed institutional funding or customer revenue reported in third-party press.
Could AI replace what Remedy does?
Remedy's own product is the commodity layer at risk: routine pharmacy call-intake is already shipped as a template by Retell AI and PolyAI by mid-2026, and identical workflows are offered by Pharmie AI, Asepha, and Hippocratic AI, leaving Remedy with low differentiation.
Has Remedy raised a seed round?
No independently confirmed institutional seed round exists as of 2026-07-08. One aggregator-only estimate cites $11.9M, but this figure lacks a primary source and is unverified, so it should not be treated as confirmed funding.
Who is Remedy's biggest competitor?
Asepha, which raised a $4M seed round on 2025-07-14 (5x oversubscribed, led by Glasswing Ventures) and claims Fortune 50 customers, and Hippocratic AI, which closed a $141M Series B at a $1.64B valuation in January 2025, both target the same pharmacy call-automation niche.
What does Remedy's product actually do?
Remedy's AI voice agent, 'Remy,' answers routine inbound pharmacy calls, handling refill requests, prescription status, transfers, and insurance questions, while explicitly refusing dosage questions, urgent symptoms, or prescription changes, per its site as of 2026-07-08.
Who owns or founded Remedy?
Remedy is founder-led by CEO Vishnu Sreenivasan, whose YC profile references Brown University, OpenAI, and NASA experience, alongside a PharmD-candidate co-founder handling clinical operations, per Y Combinator's listing as of 2026-07-08.
Timeline
  • 2026-06-30Retell AI and PolyAI reported to have shipped pharmacy-refill-specific voice templates
  • 2026-04-29Utah allows Doctronic AI to autonomously renew chronic prescriptions, covering ~80% of pilot renewals
  • 2026-04-07Large 7,000+ store US pharmacy chain reported using in-house AI voice for 1M+ calls/day
  • 2025-09Remedy joins Y Combinator Fall 2025 (F25) batch
  • 2025-07-14Asepha raises $4M seed, 5x oversubscribed, plans to double staff and open NY office
  • 2025-01-01Hippocratic AI closes $141M Series B at $1.64B valuation
Revision history
27 July 2026
First assessed. Little protection left. The text above is fixed as of this date and is not edited afterwards.
In the same band
ExonicOpenrollSemiotic
More in YC Fall 2025 →
Sources